News coverage about Cepheid (NASDAQ:CPHD) has been trending somewhat negative on Thursday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cepheid earned a coverage optimism score of -0.05 on Accern’s scale. Accern also assigned media stories about the scientific and technical instruments company an impact score of 47.4107425351818 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
CPHD remained flat at $$52.95 during trading on Thursday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.24 and a current ratio of 4.30. Cepheid has a 1-year low of $25.09 and a 1-year high of $53.91.
Cepheid Company Profile
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.